3 Stock Picks: Visa, Roblox, and Altria
Last week, three companies posted quarterly results that reiterate their fundamental strengths.Credit card firm Visa (V) struggled to hold the $350 share price despite posting an EPS of $2.98 (non-GAAP). Revenue was $10.2 billion (+14.6% Y/Y). The firm beat on the top line and bottom line.Visa’s Q3 strength is due to lower incentives, higher currency volatility, and strong value-added services. However, operating expenses came in higher than management expected. Personnel costs increased. This suggests that customer service quality rises, improving future returns.Gaming firm Roblox (RBLX) dipped after posting $0.41 EPS in losses. However, revenue increased by 21% Y/Y to $1.08 billion. Average daily active users were 111.8 million (+41% Y/Y). Unique payers were up by 58%. Share dilution through stock-based compensation is an ongoing risk.Tobacco firm Altria (MO) reported a -1.8% Y/Y in revenue of $6.1 billion. Net revenue fell after smokeable product sales fell. Oral tobacco product sales offset that decline. Still, Altria increased its 2025 full-year guidance. It lifted its EPS target to $5.35 - $5.45, which represents a 3% - 5% growth rate.Consumers like the NJOY smokeless product experience. As Altria markets that brand further, expect the company to raise its guidance next quarter.Income investors may consider Philip Morris (PM) and British American Tobacco (BTI). Although their yield is below 6% compared to Altria’s 6.7% rate, they offer steady, compounded annual growth.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


